{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:26:23Z","timestamp":1783776383687,"version":"3.55.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3\u2032,5\u2032-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Beh\u00e7et\u2019s syndrome. Compared to conventional immunosuppressive therapies, apremilast has better safety and tolerability profiles that significantly reduce the risk of serious adverse reactions from long-term usage. Apremilast shows easier and faster absorption even by special areas of the body, such as nails, scalp, palms and soles of feet, and genitals, along with clinically meaningful improvements. More recently, accumulating real-world evidence has revealed that it is highly effective for treating multiple immune-mediated inflammatory skin diseases in an off-label manner; it also appears to be useful either alone or as an add-on treatment against some chronic inflammatory skin disorders recalcitrant to conventional therapies. Thus, further large-scale studies and real-life trials are necessary to better elucidate its role in dermatology. The present narrative review provides an overview of apremilast as a novel therapeutic option for skin disorders, including a comprehensive look at its pharmacology, clinical efficacy, and safety profile, with the aim of enlightening clinicians on the broad applications and full potential of this small-molecule drug based on currently available evidence.<\/jats:p>","DOI":"10.3389\/fphar.2025.1633426","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T08:12:29Z","timestamp":1755763949000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoqian","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiecheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","article-title":"Long-term treatment with apremilast in hidradenitis suppurativa: a 2-year follow-up of initial responders","volume":"85","author":"Aarts","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaad.2017.03.020","article-title":"Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses","volume":"77","author":"Abrouk","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3315\/jdcr.2016.1232","article-title":"Treatment of recalcitrant erosive oral Lichen planus and desquamative gingivitis with oral apremilast","volume":"10","author":"AbuHilal","year":"2016","journal-title":"J. Dermatol. Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bjd.16071","article-title":"Successful treatment of SAPHO syndrome with apremilast","volume":"179","author":"Adamo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e15743","DOI":"10.1111\/dth.15743","article-title":"Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast","volume":"35","author":"Agud\u2010Dios","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B6","article-title":"Apremilast in refractory orogenital ulcers and other manifestations of Beh\u00e7et's disease","volume-title":"National multicenter study of 51 cases in clinical practice","author":"Atienza-Mateo","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jdcr.2023.06.033","article-title":"The successful use of oral apremilast for a case of dissecting cellulitis","volume":"39","author":"Bernard","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B11","first-page":"1026","article-title":"Oral Lichen planus treated with apremilast","volume":"15","author":"Bettencourt","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/ijd.17185","article-title":"Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer-blinded comparative study","volume":"63","author":"Bhat","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","article-title":"Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients","volume":"5","author":"Bitar","year":"2019","journal-title":"JAAD Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jamadermatol.2022.3917","article-title":"Apremilast in recalcitrant cutaneous dermatomyositis: a nonrandomized controlled trial","volume":"158","author":"Bitar","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jdcr.2022.10.001","article-title":"Treatment of pyoderma gangrenosum with apremilast monotherapy","volume":"30","author":"Bordeaux","year":"2022","journal-title":"JAAD Case Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.55563\/clinexprheumatol\/e3gjax","article-title":"Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease","volume":"41","author":"Cabas","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S561","DOI":"10.1097\/RHU.0000000000000999","article-title":"Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast","volume":"27","author":"Charlton","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13082","DOI":"10.1111\/dth.13082","article-title":"Steroid-resistant alopecia totalis in a child successfully treated with oral apremilast and platelet-rich plasma therapy","volume":"32","author":"Chhabra","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1203475419878162","article-title":"Recalcitrant seborrheic dermatitis successfully treated with apremilast","volume":"24","author":"Cohen","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1111\/jdv.18906","article-title":"Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis","volume":"37","author":"Cunningham","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/rheumatology\/kez267","article-title":"Efficacy and safety of apremilast for Beh\u00e7et's syndrome: a real-life single-centre Italian experience","volume":"59","author":"De Luca","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1524-4725.2012.02539.x","article-title":"Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study","volume":"11","author":"De Souza","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3892\/etm.2018.6989","article-title":"Biological therapies for atopic dermatitis: an update","volume":"17","author":"Deleanu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12967-016-0938-1","article-title":"Activation of myeloid dendritic cells, effector cells and regulatory T cells in Lichen planus","volume":"14","author":"Domingues","year":"2016","journal-title":"J. Transl. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase iii, randomised, controlled trial (palace 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/CCID.S382628","article-title":"Advancements in the treatment of cutaneous lupus erythematosus and dermatomyositis: a review of the literature","volume":"15","author":"Elhage","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/ijt.ijt_59_19","article-title":"Apremilast in refractory alopecia areata","volume":"11","author":"Estebanez","year":"2019","journal-title":"Int. J. Trichol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5070\/d3235034926","article-title":"Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report","volume":"23","author":"Farahnik","year":"2017","journal-title":"Dermatol. Online J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","article-title":"Vitiligo: mechanistic insights lead to novel treatments","volume":"140","author":"Frisoli","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03009742.2021.1929458","article-title":"A novel combination treatment with apremilast and tumor necrosis factor inhibitor for a patient with refractory intestinal Behcet's disease","volume":"51","author":"Fukui","year":"2022","journal-title":"Scand. J. Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.adengl.2021.09.009","article-title":"Hidradenitis suppurativa treated with apremilast: a case series","volume":"112","author":"Garbayo-Salmons","year":"2021","journal-title":"Actas Dermosifiliogr. English Ed."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e18991","DOI":"10.1097\/MD.0000000000018991","article-title":"Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: case report and review of literature","volume":"99","author":"Garcovich","year":"2020","journal-title":"Med. Baltim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.21873\/invivo.11108","article-title":"Elevated IL-4 and IFN-Gamma levels in muscle tissue of patients with dermatomyositis","volume":"31","author":"Giris","year":"2017","journal-title":"Vivo"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/T(H)17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/odi.13741","article-title":"An appraisal of highest quality studies reporting malignant transformation of oral Lichen planus based on a systematic review","volume":"27","author":"Gonzalez-Moles","year":"2021","journal-title":"Oral Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1111\/jocd.15903","article-title":"The relative efficacy of monotherapy with janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: network meta-analyses of clinical trials","volume":"22","author":"Gupta","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","article-title":"Apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","volume":"39","author":"Hatemi","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e002235","DOI":"10.1136\/rmdopen-2022-002235","article-title":"Impact of apremilast on quality of life in Beh\u00e7et's syndrome: analysis of the phase 3 RELIEF study","volume":"8","author":"Hatemi","year":"2022","journal-title":"RMD Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19378","DOI":"10.1038\/s41598-023-46737-1","article-title":"Antifibrotic effect of apremilast in systemic sclerosis dermal fibroblasts and bleomycin-induced mouse model","volume":"13","author":"Higuchi","year":"2023","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/14397595.2020.1830504","article-title":"Efficacy and safety of apremilast for 3 months in beh\u00e7et's disease: a prospective observational study","volume":"31","author":"Hirahara","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1111\/1346-8138.14766","article-title":"Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis","volume":"46","author":"Ichiyama","year":"2019","journal-title":"J. Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/mr\/roab098","article-title":"Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with beh\u00e7et's disease: a systematic review and meta-analysis","volume":"32","author":"Iizuka","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jdcr.2023.06.011","article-title":"Apremilast for the treatment of generalized granuloma annulare: a case series of 8 patients","volume":"38","author":"Joshi","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e13809","DOI":"10.1111\/dth.13809","article-title":"Successful use of apremilast as a steroid-sparing agent in chronic actinic dermatitis","volume":"33","author":"Kaushik","year":"","journal-title":"Dermatol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e14345","DOI":"10.1111\/dth.14345","article-title":"Apremilast in orofacial granulomatosis\u2014A report of five cases","volume":"33","author":"Kaushik","year":"","journal-title":"Dermatol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B48","first-page":"170","article-title":"Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study","volume":"18","author":"Kerdel","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdermsci.2014.11.009","article-title":"The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo","volume":"77","author":"Keren","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","article-title":"Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study","volume":"140","author":"Khemis","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00403-022-02343-1","article-title":"Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV\u2013VI","volume":"315","author":"Kim","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jdcr.2023.05.013","article-title":"Crushed apremilast for the treatment of oral Lichen planus","volume":"37","author":"Kim-Lim","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"240","DOI":"10.25259\/IJDVL_83_2023","article-title":"Darier disease responding to apremilast: report of two cases","volume":"90","author":"Kleidona","year":"2024","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e15138","DOI":"10.1111\/dth.15138","article-title":"A narrative review of therapies for scalp dermatomyositis","volume":"34","author":"Kolla","year":"2021","journal-title":"Dermatol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/1346-8138.16179","article-title":"Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: a phase 1b clinical trial","volume":"49","author":"Konishi","year":"2022","journal-title":"J. Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamadermatol.2015.3405","article-title":"Treatment of refractory Pityriasis rubra pilaris with novel phosphodiesterase 4 (PDE4) inhibitor apremilast","volume":"152","author":"Krase","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e13089","DOI":"10.1111\/dth.13089","article-title":"One drug and two diseases: a case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast","volume":"32","author":"Lanna","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bjd.18264","article-title":"Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata","volume":"182","author":"Laufer Britva","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/art.42486","article-title":"Reduction of neutrophil activation by phosphodiesterase 4 blockade in Behcet's disease","volume":"75","author":"Le Joncour","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jaad.2017.05.034","article-title":"Lack of efficacy of apremilast in 9 patients with severe alopecia areata","volume":"77","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","article-title":"Real-world effectiveness of apremilast in multirefractory mucosal involvement of beh\u00e7et's disease","volume":"78","author":"Lopalco","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/rheumatology\/keae274","article-title":"Exploring relief for beh\u00e7et's disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast","volume":"64","author":"Lopalco","year":"2025","journal-title":"Rheumatol. Oxf."},{"key":"B63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ajd.12934","article-title":"Improvement of alopecia areata with apremilast","volume":"60","author":"Magdaleno-Tapial","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/ajd.13253","article-title":"Improvement of recalcitrant sneddon-wilkinson disease with apremilast","volume":"61","author":"Magdaleno-Tapial","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1111\/ijd.16548","article-title":"Efficacy of apremilast in a case of resistant linear IgA bullous disease","volume":"62","author":"Maione","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e12923","DOI":"10.1111\/dth.12923","article-title":"Apremilast is effective in controlling the progression of adult vitiligo: a case series","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.55563\/clinexprheumatol\/7f4fzu","article-title":"Secretagogue effect of PDE4 inhibitor apremilast on human salivary gland organoids obtained from primary Sj\u00f6gren\u2019s syndrome patients","volume":"41","author":"Manfr\u00e8","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jdcr.2021.08.031","article-title":"Treatment of a perforating dermatosis with apremilast","volume":"16","author":"McMichael","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00403-018-1876-y","article-title":"A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata","volume":"311","author":"Mikhaylov","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e12879","DOI":"10.1111\/dth.12879","article-title":"Chronic hand eczema and hepatogenic pruritus with good response to apremilast","volume":"32","author":"Navarro-Trivino","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-1665","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo","year":"2019","journal-title":"F1000Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1080\/14656566.2021.1939307","article-title":"An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Beh\u00e7et's syndrome","volume":"22","author":"Ozdede","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (pde4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase iii, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [esteem] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaad.2012.07.014","article-title":"An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series","volume":"68","author":"Paul","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase iii, randomized controlled trial (esteem 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/ddg.14696","article-title":"Apremilast in oral Lichen planus - a multicentric, retrospective study","volume":"20","author":"Perschy","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"B80","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/odi.12094","article-title":"Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral Lichen planus","volume":"20","author":"Piccinni","year":"2014","journal-title":"Oral Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1684\/ejd.2023.4407","article-title":"Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France","volume":"33","author":"Podevin","year":"2023","journal-title":"Eur. J. Dermatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e13448","DOI":"10.1111\/dth.13448","article-title":"A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS","volume":"33","author":"Proietti","year":"2020","journal-title":"Dermatol. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-Week results from a phase iiib, randomized, placebo-controlled trial (Liberate)","volume":"31","author":"Reich","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and May serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/jdv.19964","article-title":"A ranking of treatment efficacy in alopecia areata is not possible without head-to-head studies","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1684\/ejd.2019.3576","article-title":"Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata","volume":"29","author":"Sakakibara","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch. Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"386","DOI":"10.23736\/S0392-0488.20.06640-7","article-title":"Apremilast and its role in psoriatic arthritis","volume":"155","author":"Sandhu","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000446836","article-title":"Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients","volume":"8","author":"Saporito","year":"2016","journal-title":"Case Rep. Dermatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell. Signal"},{"key":"B92","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40268-019-00284-1","article-title":"Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces antigen-induced atopic dermatitis in mice","volume":"19","author":"Schafer","year":"2019","journal-title":"Drugs R. D."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e37180","DOI":"10.7759\/cureus.37180","article-title":"Apremilast add-on benefits over conventional drugs (ABCD) in unstable non-segmental vitiligo: a 12-week single-center randomized controlled trial","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"B94","doi-asserted-by":"publisher","first-page":"398","DOI":"10.25259\/IJDVL_799_2024","article-title":"Apremilast versus betamethasone oral mini-pulse in the treatment of progressive non-segmental vitiligo: a randomised pilot trial","volume":"91","author":"Sharma","year":"2025","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-022-35741-0","article-title":"Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus","volume":"14","author":"Sigmund","year":"2023","journal-title":"Nat. Commun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4103\/ijd.ijd_499_23","article-title":"Apremilast in oral lichen planus: report of two cases and review of literature","volume":"68","author":"Sil","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s13063-021-05428-w","article-title":"Apremilast for genital erosive Lichen planus in women (the AP-GELP study): study protocol for a randomised placebo-controlled clinical trial","volume":"22","author":"Skullerud","year":"2021","journal-title":"Trials"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ced\/llae494","article-title":"Apremilast in chronic graft-versus-host disease: a paediatric case report","volume":"50","author":"Sobral-Costas","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13555-022-00877-w","article-title":"Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta-analysis","volume":"13","author":"Spencer","year":"2023","journal-title":"Dermatol. Ther. Heidelb."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/mr\/roab008","article-title":"Apremilast in a Japanese subgroup with Beh\u00e7et's syndrome: results from a phase 3, randomised, double-blind, placebo-controlled study","volume":"32","author":"Takeno","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/09546634.2019.1616046","article-title":"Apremilast is efficacious in refractory alopecia areata","volume":"31","author":"Taneja","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"B105","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40257-024-00878-9","article-title":"Lichen planus: what is new in diagnosis and treatment?","volume":"25","author":"Tekin","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/bjd.15607","article-title":"The pathogenesis of dermatomyositis","volume":"179","author":"Thompson","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"adv00118","DOI":"10.2340\/00015555-3461","article-title":"Efficacy of apremilast in patients with prurigo nodularis: a proof-of-concept study","volume":"100","author":"Todberg","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis","volume":"19","author":"Torres","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e2022179","DOI":"10.5826\/dpc.1204a179","article-title":"Apremilast in psoriasis patients with serious comorbidities: a case series and systematic review of literature","volume":"12","author":"Tsentemeidou","year":"2022","journal-title":"Dermatol. Pract. Concept"},{"key":"B110","doi-asserted-by":"publisher","first-page":"626792","DOI":"10.3389\/fimmu.2020.626792","article-title":"Apremilast in refractory beh\u00e7et's syndrome: a multicenter observational study","volume":"11","author":"Vieira","year":"2020","journal-title":"Front. Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2147\/CCID.S390591","article-title":"Evaluation of the efficacy and safety of apremilast in the management of Lichen planus","volume":"15","author":"Viswanath","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/jdv.15354","article-title":"Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers","volume":"33","author":"Vossen","year":"","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"","journal-title":"J. Am. Acad. Dermatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e15616","DOI":"10.1111\/dth.15616","article-title":"Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Beh\u00e7et's disease","volume":"35","author":"Wakiya","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/jop.12405","article-title":"Role of distinct CD4+ T helper subset in pathogenesis of oral Lichen planus","volume":"45","author":"Wang","year":"2016","journal-title":"J. Oral Pathol. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1684\/ejd.2020.3749","article-title":"Apremilast for extensive and treatment-resistant alopecia areata: a retrospective analysis of five patients","volume":"30","author":"Weber","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/ced\/llad265","article-title":"Apremilast for the treatment of papuloerythroderma of ofuji","volume":"48","author":"Yin","year":"2023","journal-title":"Clin. Exp. Dermatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1633426\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T08:12:31Z","timestamp":1755763951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1633426\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":119,"alternative-id":["10.3389\/fphar.2025.1633426"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1633426","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1633426"}}